Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain

International Journal of Clinical Practice

Volumn 69, Issue 7, 2015, Pages 738-742

  Walton, T A ^a   Nishtar, S ^b   Lumb, P J ^c   Crook, M A ^c   Marber, M S ^a   Gill, J ^a   Wierzbicki, A S ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b Heartfile Pakistan   (Pakistan)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; SIALIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ANGIOGRAPHY; ARTICLE; ATHEROMA; BIOCHEMISTRY; BLOOD LEVEL; BLOOD PRESSURE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; ENVIRONMENTAL FACTOR; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; GENSINI SCORE; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PAKISTANI; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 BLOOD LEVEL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHEST PAIN; CHRONIC PAIN; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FOLLOW UP; INCIDENCE; MIDDLE AGED; PAKISTAN; PLAQUE, ATHEROSCLEROTIC; PROCEDURES; PROGNOSIS; RISK ASSESSMENT;

BIOMARKERS; CASE-CONTROL STUDIES; CHEST PAIN; CHRONIC PAIN; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PAKISTAN; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; PROPROTEIN CONVERTASE 9; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84933277172     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12615     Document Type: Article

References (29)

1. Bhopal R, Unwin N, White M, et al., Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ 1999; 319: 215-20.
2. Tillin T, Forouhi N, Johnston DG, et al., Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study. Diabetologia 2005; 48: 649-56.
3. Tillin T, Hughes AD, Whincup P, et al., Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a UK tri-ethnic prospective cohort study (SABRE-Southall And Brent REvisited). Heart 2014; 100: 60-7.
4. Forouhi NG, Sattar N, Tillin T, et al., Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies, UK. Diabetologia 2006; 49: 2580-8.
5. Dodani S, Mistry R, Khwaja A, et al., Prevalence and awareness of risk factors and behaviours of coronary heart disease in an urban population of Karachi, the largest city of Pakistan: a community survey. J Public Health (Oxf) 2004; 26: 245-9.
6. Patel JV, Vyas A, Cruickshank JK, et al., Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis 2006; 185: 297-306.
7. Enas EA, Garg A, Davidson MA, et al., Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J 1996; 48: 343-53.
8. Nishtar S, Wierzbicki AS, Lumb PJ, et al., Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. Curr Med Res Opin 2004; 20: 55-62.
9. Lambert G, Sjouke B, Choque B, et al., The PCSK9 decade. J Lipid Res 2012; 53: 2515-24.
10. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH,. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
11. Abifadel M, Varret M, Rabes JP, et al., Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-6.
12. Wierzbicki AS, Hardman TC, Viljoen A,. Inhibition of pro-protein convertase subtilisin kexin-9 (PCSK9) as a treatment for hyperlipidaemia. Expert Opin Investig Drugs 2012; 21: 667-76.
13. Lambert G, Petrides F, Chatelais M, et al., Elevated plasma PCSK9 is equally detrimental for non-familial hypercholesterolemic (non-FH) and heterozygous FH patients, irrespective of their LDL receptor defects. J Am Coll Cardiol 2014; 63: 2365-73.
14. Matthews DR, Hosker JP, Rudenski AS, et al., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
15. Levey AS, Bosch JP, Lewis JB, et al., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
16. Alberti KG, Zimmet P, Shaw J,; Group IDFETFC. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62.
17. Alberti KG, Eckel RH, Grundy SM, et al., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
18. Gensini GG,. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
19. Wierzbicki AS, Nishtar S, Lumb PJ, et al., Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort. Int J Clin Pract 2008; 62: 701-7.
20. Dubuc G, Tremblay M, Pare G, et al., A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010; 51: 140-9.
21. Persson L, Henriksson P, Westerlund E, et al., Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arterioscler Thromb Vasc Biol 2012; 32: 810-4.
22. Brouwers MC, Troutt JS, van Greevenbroek MM, et al., Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study. Atherosclerosis 2011; 217: 263-7.
23. Werner C, Hoffmann MM, Winkler K, et al., Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol 2014; 62: 94-102.
24. Liu S, Vaziri ND,. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant 2014; 29: 538-43.
25. Li S, Guo YL, Xu RX, et al., Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiol 2014; 174: 863-4.
26. Huijgen R, Boekholdt SM, Arsenault BJ, et al., Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol 2012; 59: 1778-84.
27. Raal FJ, Giugliano RP, Sabatine MS, et al., Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63: 1278-88.
28. Raal F, Panz V, Immelman A, Pilcher G,. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2013; 2: e000028.
29. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. Am J Cardiol 1997; 79: 756-62.